Hecate-CGβ conjugate and gonadotropin suppression shows two distinct mechanisms of action in the treatment of adrenocortical tumors in transgenic mice expressing Simian Virus 40 T antigen under inhibin-α promoter

Endocrine-Related Cancer

Volumn 16, Issue 2, 2009, Pages 549-564

  Vuorenoja, Susanna ^a   Mohanty, Bidut Prava ^a   Arola, Johanna ^b   Huhtaniemi, Ilpo ^a,c   Toppari, Jorma ^a   Rahman, Nafis A ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN ANTAGONIST; HECATE CHORIONIC GONADOTROPIN BETA; INHIBIN; INHIBIN ALPHA; LUTEINIZING HORMONE; PROGESTERONE; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR GATA 6; UNCLASSIFIED DRUG; VIRUS T ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; DRUG DERIVATIVE; GONADORELIN; GONADOTROPIN; HECATE CHORIONIC GONADOTROPIN BETA SUBUNIT CONJUGATE; HECATE-CHORIONIC GONADOTROPIN BETA-SUBUNIT CONJUGATE; INHIBIN ALPHA SUBUNIT; INHIBIN-ALPHA SUBUNIT; MELITTIN; MESSENGER RNA;

ADRENAL CORTEX TUMOR; ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; EXPRESSION VECTOR; FEMALE; HISTOPATHOLOGY; HORMONE INHIBITION; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PROGESTERONE BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SIMIAN VIRUS 40; TRANSGENIC MOUSE; TREATMENT DURATION; ANIMAL; BLOOD; C57BL MOUSE; ENZYME IMMUNOASSAY; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROMOTER REGION;

ADRENAL CORTEX NEOPLASMS; ANIMALS; ANTIGENS, VIRAL, TUMOR; CELL PROLIFERATION; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; FEMALE; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBINS; MALE; MELITTEN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROGESTERONE; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMIAN VIRUS 40;

EID: 67650477273     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0232     Document Type: Article

References (76)

1. Arrowood MJ, Jaynes JM & Healey MC 1991a Hemolytic properties of lytic peptides active against the sporozoites of Cryptosporidium parvum. Journal of Protozoology 38 161S-163S.
2. Arrowood MJ, Jaynes JM & Healey MC 1991b In vitro activities of lytic peptides against the sporozoites of Cryptosporidium parvum. Antimicrobial Agents and Chemotherapy 35 224-227.
3. Baghian A, Kousoulas K, Truax R & Storz J 1996 Specific antigens of Chlamydia pecorum and their homologues in C. psittaci and C. trachomatis. American Journal of Veterinary Research 57 1720-1725.
4. Barbosa AS, Giacaglia LR, Martin RM, Mendonca BB & Lin CJ 2004 Assessment of the role of transcript for GATA-4 as a marker of unfavorable outcome in human adrenocortical neoplasms. BMC Endocrine Disorders 4 3.
5. Bodek G, Rahman NA, Zaleska M, Soliymani R, Lankinen H, Hansel W, Huhtaniemi I & Ziecik AJ 2003 A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using hecate-CGβ conjugate. Breast Cancer Research and Treatment 79 1-10.
6. Bodek G, Kowalczyk A, Waclawik A, Huhtaniemi I & Ziecik AJ 2005a Targeted ablation of prostate carcinoma cells through LH receptor using Hecate-CGβ conjugate: functional characteristic and molecular mechanism of cell death pathway. Experimental Biology and Medicine 230 421-428.
7. Bodek G, Vierre S, Rivero-Muller A, Huhtaniemi I, Ziecik AJ & Rahman NA 2005b A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice. Neoplasia 7 497-508.
8. Bourdeau I, D'Amour P, Hamet P, Boutin JM & Lacroix A 2001 Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 86 5534-5540.
9. van Casteren JI, Schoonen WG & Kloosterboer HJ 2000 Development of time-resolved immunofluorometric assays for rat follicle-stimulating hormone and luteinizing hormone and application on sera of cycling rats. Biology of Reproduction 62 886-894.
10. Cattanach BM, Iddon CA, Charlton HM, Chiappa SA & Fink G 1977 Gonadotrophin-releasing hormone deficiency in a mutant mouse with hypogonadism. Nature 269 338-340.
11. Chen HM, Chan SC, Lee JC, Chang CC, Murugan M & Jack RW 2003 Transmission electron microscopic observations of membrane effects of antibiotic cecropin B on Escherichia coli. Microscopy Research and Technique 62 423-430.
12. Detti L, Ambler DR, Yelian FD, Kruger ML, Diamond MP & Puscheck EE 2008 Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes. Journal of Assisted Reproduction and Genetics 25 177-181.
13. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M & Allolio B 2006 Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 91 4501-4504.
14. Feelders RA, Lamberts SW, Hofland LJ, van Koetsveld PM, Verhoef-Post M, Themmen AP, de Jong FH, Bonjer HJ, Clark AJ, van der Lely AJ et al. 2003 Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. Journal of Clinical Endocrinology and Metabolism 88 230-237.
15. Gawronska B, Leuschner C, Enright FM & Hansel W 2002 Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecological Oncology 85 45-52.
16. Gittelman M, Pommerville PJ, Persson BE, Jensen JK & Olesen TK 2008 A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. Journal of Urology 180 1986-1992.
17. Givens JR, Andersen RN, Wiser WL, Donelson AJ & Coleman SA 1975Atestosterone-secreting, gonadotropin-responsive pure thecoma and polycystic ovarian disease. Journal of Clinical Endocrinology and Metabolism 41 845-853.
18. Goodarzi MO, Dawson DW, Li X, Lei Z, Shintaku P, Rao CV & Van Herle AJ 2003 Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. Journal of Clinical Endocrinology and Metabolism 88 73-77.
19. Haapasalo H, Collan Y, Montironi R, Pesonen E & Atkin NB 1990 Consistency of quantitative methods in ovarian tumor histopathology. International Journal of Gynecological Pathology 9 208-216.
20. Haavisto AM, Pettersson K, Bergendahl M, Perheentupa A, Roser JF & Huhtaniemi I 1993 A supersensitive immunofluorometric assay for rat luteinizing hormone. Endocrinology 132 1687-1691.
21. Hanahan D 1989 Transgenic mice as probes into complex systems. Science 246 1265-1275.
22. Hansel W, Leuschner C, Gawronska B & Enright F 2001 Targeted destruction of prostate cancer cells and xenografts by lytic peptide-β LH conjugates. Reproductive Biology 1 20-32.
23. Hansel W, Leuschner C & Enright F 2007a Conjugates of lytic peptides and LHRH or βCG target and cause necrosis of prostate cancers and metastases. Molecular and Cellular Endocrinology 269 26-33.
24. Hansel W, Enright F & Leuschner C 2007b Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Molecular and Cellular Endocrinology 260-262 183-189.
25. Henk WG, Todd WJ, Enright FM & Mitchell PS 1995 The morphological effects of two antimicrobial peptides, hecate-1 and melittin, on Escherichia coli. Scanning Microscopy 9 501-507.
26. Hogan B, Beddington R, Constantini F & Lacy E 1994 Manupulating the Mouse Embryo. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
27. Howard CV & Reed MG 1998 Unbiased Stereology: Three-Dimensional Measurement in Microscopy. Oxford: BIOS Scientific Publishers Limited.
28. Huhtaniemi I, White R, McArdle CA & Persson BE 2009 Will GnRH antagonists improve prostate cancer treatment? Trends in Endocrinology and Metabolism 20 43-50.
29. Kananen K, Markkula M, Rainio E, Su JG, Hsueh AJ & Huhtaniemi IT 1995 Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin- responsive granulosa cell lines. Molecular Endocrinology 9 616-627.
30. Kananen K, Markkula M, Mikola M, Rainio EM, McNeilly A & Huhtaniemi I 1996a Gonadectomy permits adrenocortical tumorigenesis in mice transgenic for the mouse inhibin alpha-subunit promoter/simian virus 40 T-antigen fusion gene: evidence for negative autoregulation of the inhibin alpha-subunit gene. Molecular Endocrinology 10 1667-1677.
31. Kananen K, Markkula M, El-Hefnawy T, Zhang FP, Paukku T, Su JG, Hsueh AJ & Huhtaniemi I 1996b The mouse inhibin alpha-subunit promoter directs SV40 T-antigen to Leydig cells in transgenic mice. Molecular and Cellular Endocrinology 119 135-146.
32. Kananen K, Rilianawati, Paukku T, Markkula M, Rainio EM & Huhtanemi I 1997 Suppression of gonadotropins inhibits gonadal tumorigenesis in mice transgenic for the mouse inhibin alpha-subunit promoter/simian virus 40 T-antigen fusion gene. Endocrinology 138 3521-3531.
33. Kero J, Poutanen M, Zhang FP, Rahman N, McNicol AM, Nilson JH, Keri RA & Huhtaniemi IT 2000 Elevated luteinizing hormone induces expression of its receptor and promotes steroidogenesis in the adrenal cortex. Journal of Clinical Investigation 105 633-641.
34. Kiiveri S, Siltanen S, Rahman N, Bielinska M, Lehto VP, Huhtaniemi IT, Muglia LJ, Wilson DB & Heikinheimo M 1999 Reciprocal changes in the expression of transcription factors GATA-4 and GATA-6 accompany adrenocortical tumorigenesis in mice and humans. Molecular Medicine 5 490-501.
35. Kiiveri S, Liu J, Westerholm-Ormio M, Narita N, Wilson DB, Voutilainen R & Heikinheimo M 2002 Differential expression of GATA-4 and GATA-6 in fetal and adult mouse and human adrenal tissue. Endocrinology 143 3136-3143.
36. Kiiveri S, Liu J, Arola J, Heikkila P, Kuulasmaa T, Lehtonen E, Voutilainen R & Heikinheimo M 2005 Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors. Molecular and Cellular Endocrinology 233 47-56.
37. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK & Schroder FH 2008 The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU International 102 1531-1538.
38. Korkut E, Bokser L, Comaru-Schally AM, Groot K & Schally AV 1991 Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75. PNAS 88 844-848.
39. Kuruba R & Gallagher SF 2008 Current management of adrenal tumors. Current Opinion in Oncology 20 34-46.
40. Lacroix A, Hamet P & Boutin JM 1999 Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome. New England Journal of Medicine 341 1577-1581.
41. Lainas TG, Sfontouris IA, Papanikolaou EG, Zorzovilis JZ, Petsas GK, Lainas GT & Kolibianakis EM 2008 Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial. Human Reproduction 23 1355-1358.
42. de Lange WE, Pratt JJ & Doorenbos H 1980 A gonadotrophin responsive testosterone producing adrenocortical adenoma and high gonadotrophin levels in an elderly woman. Clinical Endocrinology 12 21-28.
43. Larson BA, Vanderlaan WP, Judd HL & McCullough DL 1976 A testosterone-producing adrenal cortical adenoma in an elderly woman. Journal of Clinical Endocrinology and Metabolism 42 882-887.
44. Leinonen P, Ranta T, Siegberg R, Pelkonen R, Heikkila P & Kahri A 1991 Testosterone-secreting virilizing adrenal adenoma with human chorionic gonadotrophin receptors and 21-hydroxylase deficiency. Clinical Endocrinology 34 31-35.
45. Lepor H 2006 The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Reviews in Urology 8 183-189.
46. Leuschner C & Hansel W 2004 Membrane disrupting lytic peptides for cancer treatments. Current Pharmaceutical Design 10 2299-2310.
47. Leuschner C & Hansel W 2005 Targeting breast and prostate cancers through their hormone receptors. Biology of Reproduction 73 860-865.
48. Leuschner C, Enright FM, Melrose PA & Hansel W 2001 Targeted destruction of androgen-sensitive and insensitive prostate cancer cells and xenografts through luteinizing hormone receptors. Prostate 46 116-125.
49. Leuschner C, Enright FM, Gawronska B & Hansel W 2003 Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo. Breast Cancer Research and Treatment 78 17-27.
50. Mijnhout GS, Danner SA, van de Goot FR & van Dam EW 2004 Macronodular adrenocortical hyperplasia in a postmenopausal woman. Netherlands Journal of Medicine 62 454-455.
51. Mikola M, Kero J, Nilson JH, Keri RA, Poutanen M & Huhtaniemi I 2003 High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter/Simian virus 40 T-antigen fusion gene. Oncogene 22 3269-3278.
52. Miyamura N, Taguchi T, Murata Y, Taketa K, Iwashita S, Matsumoto K, Nishikawa T, Toyonaga T, Sakakida M & Araki E 2002 Inherited adrenocorticotropin-independent macronodular adrenal hyperplasia with abnormal cortisol secretion by vasopressin and catecholamines: detection of the aberrant hormone receptors on adrenal gland. Endocrine 19 319-326.
53. Pabon JE, Li X, Lei ZM, Sanfilippo JS, Yussman MA & Rao CV 1996 Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands. Journal of Clinical Endocrinology and Metabolism 81 2397-2400.
54. Pakarainen T, Zhang FP, Nurmi L, Poutanen M & Huhtaniemi I 2005 Knockout of luteinizing hormone receptor abolishes the effects of follicle-stimulating hormone on preovulatory maturation and ovulation of mouse graafian follicles. Molecular Endocrinology 19 2591-2602.
55. Rahman NA, Kananen Rilianawati K, Paukku T, Mikola M, Markkula M, Hamalainen T & Huhtaniemi IT 1998 Transgenic mouse models for gonadal tumorigenesis. Molecular and Cellular Endocrinology 145 167-174.
56. Rahman NA, Kiiveri S, Siltanen S, Levallet J, Kero J, Lensu T, Wilson DB, Heikinheimo MT & Huhtaniemi IT 2001 Adrenocortical tumorigenesis in transgenic mice: the role of luteinizing hormone receptor and transcription factors GATA-4 and GATA-61. Reproductive Biology 1 5-9.
57. Rahman NA, Kiiveri S, Rivero-Muller A, Levallet J, Vierre S, Kero J, Wilson DB, HeikinheimoM & Huhtaniemi I 2004 Adrenocortical tumorigenesis in transgenic mice expressing the inhibin alpha-subunit promoter/simian virus 40 T-antigen transgene: relationship between ectopic expression of luteinizing hormone receptor and transcription factor GATA-4. Molecular Endocrinology 18 2553-2569.
58. Redding TW & Schally AV 1983 Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. PNAS 80 1459-1462.
59. Redding TW, Coy DH & Schally AV 1982 Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone. PNAS 79 1273-1276.
60. Rilianawati, Paukku T, Kero J, Zhang FP, Rahman N, Kananen K & Huhtaniemi I 1998 Direct luteinizing hormone action triggers adrenocortical tumorigenesis in castrated mice transgenic for the murine inhibin alphasubunit promoter/simian virus 40 T-antigen fusion gene. Molecular Endocrinology 12 801-809.
61. Rilianawati, Kero J, Paukku T & Huhtaniemi I 2000 Long-term testosterone treatment prevents gonadal and adrenal tumorigenesis of mice transgenic for the mouse inhibin-alpha subunit promoter/simian virus 40 T-antigen fusion gene. Journal of Endocrinology 166 77-85.
62. Saner-Amigh K, Mayhew BA, Mantero F, Schiavi F, White PC, Rao CV & Rainey WE 2006 Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas. Journal of Clinical Endocrinology and Metabolism 91 1136-1142.
63. Schally AV, Redding TW & Comaru-Schally AM 1983 Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate 4 545-552.
64. Schulick RD & Brennan MF 1999a Adrenocortical carcinoma. World Journal of Urology 17 26-34.
65. Schulick RD & Brennan MF 1999b Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Annals of Surgical Oncology 6 719-726.
66. Sheeler LR 1994 Cushing's syndrome and pregnancy. Endocrinology and Metabolism Clinics of North America 23 619-627.
67. Smith HC, Posen S, Clifton-Bligh P & Casey J 1978 A testosterone-secreting adrenal cortical adenoma. Australia and New Zealand Journal of Medicine 8 171-175.
68. Srkalovic G, Bokser L, Radulovic S, Korkut E & Schally AV 1990 Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Endocrinology 127 3052-3060.
69. Szende B, Srkalovic G, Groot K, Lapis K & Schally AV 1990 Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. Journal of the National Cancer Institute 82 513-517.
70. Takahashi H, Yoshizaki K, Kato H, Masuda T, Matsuka G, Mimura T, Inui Y, Takeuchi S, Adachi H & Matsumoto K 1978 A gonadotrophin-responsive virilizing adrenal tumour identified as a mixed ganglioneuroma and adreno-cortical adenoma. Acta Endocrinologica 89 701-709.
71. Terzolo M & Berruti A 2008 Adjunctive treatment of adrenocortical carcinoma. Current Opinion in Endocrinology, Diabetes and Obesity 15 221-226.
72. Utsugi T, Schroit AJ, Connor J, Bucana CD & Fidler IJ 1991 Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Research 51 3062-3066.
73. Vuorenoja S, Rivero-Muller A, Ziecik AJ, Huhtaniemi I, Toppari J & Rahman NA 2008 Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by hecate-human chorionic gonadotropin beta conjugate. Endocrine-Related Cancer 15 635-648.
74. Werk EE Jr, Sholiton LE & Kalejs L 1973 Testosterone-secreting adrenal adenoma under gonadotropin control. New England Journal of Medicine 289 767-770.
75. Wy LA, Carlson HE, Kane P, Li X, Lei ZM & Rao CV 2002 Pregnancy-associated Cushing's syndrome secondary to a luteinizing hormone/human chorionic gonadotropin receptor-positive adrenal carcinoma. Gynecological Endocrinology 16 413-417.
76. Zaleska M, Waclawik A, Bodek G, Zezula-Szpyra A, Li X, Janowski T, Hansel WH, Rahman NA & Ziecik AJ 2004 Growth repression in diethylstilbestrol/dimethylbenz[a]anthracene-induced rat mammary gland tumor using hecate-CGβ conjugate. Experimental Biology and Medicine 229 335-344.